

Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has raised $80 million in Series C financing. RA Capital Management led the round.
Source: Press Release
Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has raised $80 million in Series C financing.
Cyteir Therapeutics, a developer of next-generation synthetic lethal therapies for cancer, has raised $80 million in Series C financing. RA Capital Management led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination